Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Small Cell Lung Carcinoma

Carcinoma, Neuroendocrine

Carcinoma, Transitional Cell

Prostatic Neoplasms

Carcinoma, Small Cell

Urinary Bladder Neoplasms

Neuroendocrine Tumors

Urethral Neoplasms

Lung Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Urologic Neoplasms

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Adenocarcinoma

Neoplasms, Nerve Tissue

Urethral Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Small Cell Lung Cancer

Transitional Cell Carcinoma

Neuroendocrine Tumor

Urethral Cancer

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Dermatologic Agents

Pembrolizumab

Docetaxel

Carboplatin

Etoposide

Cisplatin

Etoposide phosphate

Podophyllotoxin

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Enzyme Inhibitors

Keratolytic Agents

Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Arnold Chin

This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes or that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as etoposide, docetaxel, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with platinum-based chemotherapy may work better in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate.

PRIMARY OBJECTIVES:

I. To evaluate the preliminary efficacy of pembrolizumab (MK-3475) in combination with standard-of-care cisplatin-based chemotherapy by assessing the durable response rate (DRR), overall response rate (ORR), duration of response (DOR), and progression free survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and overall survival (OS) in Cohorts 1 and 2, and radiographic PFS (rPFS) by Prostate Cancer Working Group 3 (PCWG3) and prostate-specific antigen (PSA) response in Cohort 2.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of pembrolizumab in combination with etoposide and cisplatin/carboplatin or docetaxel and carboplatin assessed by parameters of adverse events (AEs).

EXPLORATORY OBJECTIVES:

I. Determine correlation of biomarkers including PD-L1 expression (PD-L1 positive \>= 1% by immunohistochemistry \[IHC\] using 22C3 antibody), and serum and tissue molecular (including genomic, proteomic) biomarkers that may be indicative of clinic response or safety.

OUTLINE:

Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30 days, every 9-12 weeks for up to 2 years, and then every 12 weeks thereafter.

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

The statistical analyses will be primarily descriptive and exploratory. The proportional data (DRR) will be summarized using 95% 2-sided exact binomial confidence intervals (CIs).

ORR will be determined as the proportion of subjects who have a complete response (CR) or partial response (PR).

DOR will be defined as the time from the first documented CR or PR until radiograph disease progression or PSA progression. PSA progression will be defined as the date that an increase of 25% or more and an absolute increase of \>= 2 ng/ml above nadir occurs. Time-to-event data (DOR) will be summarized by cohort using the Kaplan-Meier method. Kaplan-Meier estimates of event rates at landmark time points (e.g., 3-,6-, and 12-months) and median time to the event will be presented with the corresponding 95% CIs.

PFS will be defined as the time from the first day of study treatment to first documented disease progression or PSA progression. Time-to-event data (PFS) will be summarized by cohort using the Kaplan-Meier method. Kaplan-Meier estimates of event rates at landmark time points (e.g., 3-,6-, and 12-months) and median time to the event will be presented with the corresponding 95% CIs.

OS is defined as the time from the first day of study treatment to the time of death from any cause. Time-to-event data (OS) will be summarized by cohort using the Kaplan-Meier method. Kaplan-Meier estimates of event rates at landmark time points (e.g., 3-,6-, and 12-months) and median time to the event will be presented with the corresponding 95% CIs.

rPFS will be defined as the time from the first day of study treatment to first documented disease progression.

Merck Sharp & Dohme LLC

Jonsson Comprehensive Cancer Center

Spots Global Cancer Trial Database for prostate small cell carcinoma